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Clinical-grade T cells are genetically modified ex vivo to
express chimeric antigen receptors (CARs) to redirect
their specificity to target tumor-associated antigens in
vivo. We have developed gene therapy approach to render
T cells specific for invasive fungal infections (IFI) due to
Aspergillus. We adapted the pattern-recognition receptor
Dectin-1 to activate T cells via chimeric CD28 and
CD3-zeta (designated D-CAR) upon binding with carbo-
hydrate cell wall in Aspergillus germlings. T cells geneti-
cally modified with Sleeping Beauty system to stably
express D-CAR were selectively propagated on artificial
antigen presenting cells using an approach that is
approved by FDA to develop CAR T cells for clinical trials.
The D-CAR+ T cells exhibited specificity for beta-1,3-
gucan and damaged and thus inhibited hyphal growth of
Aspergillus. Treatment of D-CAR+ T cells with steroids
did not compromise anti-fungal activity. Thus, we report a
clinically-appealing strategy to transfer innate immunity
for mycology to cytotoxic T cells.
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